Aux Sable Liquid Products LP v JL Energy Transportation Inc 2019 FC 581 Southcott J
2,205,670
A final point raised by Aux Sable
concerns patentable subject matter. Southcott J held Claims 9-10 to be
invalid as being addressed to non-patentable subject matter, on the
basis that “practice
of claims 9-10 to a successful outcome within the ranges of compositions
prescribed does
depend on the exercise of professional judgment” [238]. In so holding,
Southcott J relied on the
dosage range cases such as Axcan 2006 FC 527 [232], [238]. I have criticized this line of cases at
some length in this post, and I note that in Cobalt v Bayer [YAZ] 2015 FCA 116 [101] the FCA
remarked that my posts had “forcefully advanced arguments of policy and logic against the
current position.” Southcott J’s discussion was very brief — a single paragraph — and he
remarked that “little turns on the outcome of this analysis,” as he had already held these claims
invalid for other reasons [238]. Consequently, Aux Sable does not add any weight to the existing
line of cases, particularly in light of the concerns expressed by the FCA.
No comments:
Post a Comment